Six new cosmetic ingredients have completed filing in China, according to a status update from CIRS Group, adding to the pipeline of notified ingredients now available to formulators working under the country's post-CSAR registration regime.

The filings land under China's dual-track system for new cosmetic ingredients, which came into force with the Cosmetics Supervision and Administration Regulation (CSAR). Under that framework, higher-risk ingredients require registration and pre-market approval by the National Medical Products Administration (NMPA), while lower-risk ingredients follow a simpler filing route. Each newly filed ingredient becomes usable in the Chinese market after its filing enters the public inventory.

For brands and contract manufacturers selling into China, each new filed ingredient carries practical weight:

• Formulation access. A filed NCI gives R&D teams a newly cleared input for China-specific SKUs, without waiting for the longer registration track.
• Compliance workload. Formulators must still verify the filing's scope, usage conditions and any concentration limits attached to the filing before commercial use.
• Procurement planning. Ingredient suppliers behind the filings can now market the substances to Chinese cosmetics clients, and buyers can qualify them for supply chains serving the market.

Why the filing route matters

Since CSAR took effect, the filing track has become the dominant pathway for new ingredient market entry in China. The registration track — reserved for ingredients such as preservatives, UV filters, colorants, hair dyes and other higher-risk categories — demands toxicological dossiers and NMPA review that can stretch timelines considerably.

The six filings reported by CIRS Group signal continued supplier activity on this faster route. For multinationals, the calculus is straightforward: file low-risk actives and functional ingredients where possible, reserve registration for the categories that legally require it.

What should formulators and regulators watch next?

Each new filing published by the NMPA expands the official NCI inventory that Chinese regulators maintain. Formulators, regulatory affairs teams and distributors should track the inventory for:

• the six new ingredient names and their INCI equivalents, once published in the updated inventory;
• any conditions of use — maximum concentrations, application categories — attached to the filings;
• subsequent annual safety reports that filers must submit under CSAR.

The next data point to watch is the NMPA's updated new cosmetic ingredient inventory listing the six substances by name, along with the filing numbers and usage conditions that determine how broadly each can be deployed in products placed on the Chinese market.